Report Scope:

While women’s health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders. This report does not focus on drugs for infertility, diagnostic and drug technologies for breast cancer or therapies and diagnostics for ovarian cancer.

Report Includes:

  • 54 tables
  • Detailed overview of the global markets for pharmaceuticals for women’s health and identification of the main women’s health disorders
  • Analyses of market trends, with data from 2019, estimates for 2020 and projections of compound annual growth rates (CAGRs) through 2025
  • Evaluation of the impact of demographic, economic and other factors that will drive future demand in the women’s health therapeutics market
  • A look at the unmet needs in women’s health therapeutics and details of the promising new drugs and therapies that are still in development and testing stage
  • Market forecast of the potential drugs in the pipeline, information on late-stage pipeline drugs and overview of osteoporosis drug development
  • Insights into government concerns and initiatives towards women’s health
  • Highlights of current and future market potential and a detailed analysis of the current market size, and regulatory scenarios
  • Market share analysis of leading drug manufacturers and detailed coverage of women’s health therapeutics industry in terms of different events like mergers and acquisitions, agreements, collaborations, and partnerships
  • Company profiles of the leading suppliers of the industry including AbbVie Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Johnson & Johnson Inc. and Merck KGaA